Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma

Tomonori Hidaka, Shingo Nakahata, Kinta Hatakeyama, Makoto Hamasaki, Kiyoshi Yamashita, Takashi Kohno, Yasuhito Arai, Tomohiko Taki, Kazuhiro Nishida, Akihiko Okayama, Yujiro Asada, Ryoji Yamaguchi, Hirohito Tsubouchi, Jun Yokota, Masafumi Taniwaki, Yujiro Higashi, Kazuhiro Morishita

Blood (2008) 112 (2): 383–393.

https://doi.org/10.1182/blood-2008-01-131185

Published: 2008

Includes: Supplemental data

Journal Articles

Biological Pathways and In Vivo Anti-Tumor Activity Induced by Atiprimod in Multiple Myeloma (MM).

Paola Neri, MD, Pierfrancesco Tassone, MD, Masood Shammas, PhD, Hiroshi Yasui, MD, Ernestina Schipani, MD, Ramesh B. Batchu, PhD, Simona Blotta, MD, Rao Prabhala, PhD, Laurence Catley, MD, Makoto Hamasaki, MD, Teru Hideshima, MD, Dharminder Chauhan, PhD, Gary S. Jacob, PhD, Donald Picker, PhD, Salvatore Venuta, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2006) 108 (11): 3455.

https://doi.org/10.1182/blood.V108.11.3455.3455

Published: 2006

Journal Articles

In Vivo Anti-Tumor Activity of Atiprimod on SCID Models of Multiple Myeloma.

Paola Neri, MD, Pierfrancesco Tassone, MD, Masood A. Shammas, PhD, Ramesh B. Batchu, PhD, Simona Blotta, MD, Sushma Samala, PhD, Laurence Catley, MD, Makoto Hamasaki, PhD, Teru Hideshima, MD, Gary S. Jacob, PhD, Donald H. Picker, PhD, Salvatore Venuta, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2005) 106 (11): 249.

https://doi.org/10.1182/blood.V106.11.249.249

Published: 2005

Journal Articles

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

Kenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, Noopur Raje, Shaji Kumar, Hiromasa Hideshima, Norihiko Shiraishi, Hiroshi Yasui, Aldo M. Roccaro, Paul Richardson, Klaus Podar, Steven Le Gouill, Dharminder Chauhan, Kazuo Tamura, Jack Arbiser, Kenneth C. Anderson

Blood (2005) 106 (5): 1794–1800.

https://doi.org/10.1182/blood-2005-01-0346

Published: 2005

Journal Articles

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma

Hiroshi Yasui, Teru Hideshima, Makoto Hamasaki, Aldo M. Roccaro, Norihiko Shiraishi, Shaji Kumar, Pierfrancesco Tassone, Kenji Ishitsuka, Noopur Raje, Yu-Tzu Tai, Klaus Podar, Dharminder Chauhan, Lorenzo M. Leoni, Sarath Kanekal, Gary Elliott, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2005) 106 (2): 706–712.

https://doi.org/10.1182/blood-2005-02-0838

Published: 2005

Journal Articles

Azaspirane ( N-N -diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo

Makoto Hamasaki, Teru Hideshima, Pierfrancesco Tassone, Paola Neri, Kenji Ishitsuka, Hiroshi Yasui, Norihiko Shiraishi, Noopur Raje, Shaji Kumar, Donald H. Picker, Gary S. Jacob, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2005) 105 (11): 4470–4476.

https://doi.org/10.1182/blood-2004-09-3794

Published: 2005

Journal Articles

Induction of Apoptosis by Didox Via Down-Regulation of Bcl-2 Family Proteins in Multiple Myeloma (MM).

Noopur Raje, MD, Shaji Kumar, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Aldo Roccaro, MD, Hiroshi Yasui, MD, Makoto Hamasaki, MD, Norihiko Shiraisi, PhD, Nikhil C. Munshi, MD, Howard Elford, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 4842.

https://doi.org/10.1182/blood.V104.11.4842.4842

Published: 2004

Journal Articles

Bortezomib Targets Multiple Myeloma Endothelial Cells.

Aldo M. Roccaro, M.D., Teru Hideshima, M.D.Ph.D, Noopur Raje, M.D., Shaji Kumar, M.D., Kenji Ishitsuka, M.D., Hiroshi Yasui, M.D., Norihiko Shiraishi, M.D., Makoto Hamasaki, M.D., Paul G. Richardson, M.D., Kenneth C. Anderson, M.D.

Blood (2004) 104 (11): 4903.

https://doi.org/10.1182/blood.V104.11.4903.4903

Published: 2004

Journal Articles

Honokiol Overcomes Conventional Drug Resistance in Human Multiple Myeloma.

Kenji Ishitsuka, M.D., Ph.D, Teru Hideshima, M.D., Ph.D, Makoto Hamasaki, M.D., Ph.D, Raje Noopur, M.D., Ph.D, Kumar Shaji, M.D., Ph.D, Hiromasa Hideshima, Norihiko Shiraishi, Ph.D, Paul Richardson, M.D., Ph.D, Nikhil C. Munshi, M.D., Ph.D, Dharminder Chauhan, Ph.D, Jack Arbiser, M.D., Ph.D, Kenneth C. Anderson, M.D., Ph.D

Blood (2004) 104 (11): 1488.

https://doi.org/10.1182/blood.V104.11.1488.1488

Published: 2004

Journal Articles

Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.

Yu-Tzu Tai, Ph.D., Laurence Catley, M.D., Xian-Feng Li, M.S., Makoto Hamasaki, M.D., Ph.D., Klaus Podar, M.D., Ph.D., Teru Hideshima, M.D., Ph.D., Dharminder Chauhan, Ph.D., Robert Schlossman, M.D., Paul Richardson, M.D., Steven P. Streon, M.D., Ph.D., Nikhil C. Munshi, M.D., Kenneth C. Anderson, M.D.

Blood (2004) 104 (11): 1498.

https://doi.org/10.1182/blood.V104.11.1498.1498

Published: 2004

Journal Articles

The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells.

Klaus Podar, MD, PhD, Melissa Simoncini, BS, Yu-Tzu Tai, PhD, Martin Sattler, PhD, Kenji Ishitsuka, MD, PhD, Steven Le Gouill, MD, Makoto Hamasaki, MD, PhD, Renate Burger, PhD, Noopur Raje, MD, Teru C. Hideshima, MD, PhD, Dharminder Chauhan, JD, PhD, Kenneth Anderson, MD

Blood (2004) 104 (11): 3352.

https://doi.org/10.1182/blood.V104.11.3352.3352

Published: 2004

Journal Articles

In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM).

Noopur Raje, MD, Shaji Kumar, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Aldo Roccaro, MD, Hiroshi Yasui, MD, Makoto Hamasaki, MD, Norihiko Shiraishi, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Simon R. Green, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 3359.

https://doi.org/10.1182/blood.V104.11.3359.3359

Published: 2004

Journal Articles

Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma.

Hiroshi Yasui, Teru Hideshima, Aldo M. Roccaro, Norihiko Shiraishi, Makoto Hamasaki, Kenji Ishitsuka, Shaji Kumar, Noopur Raje, Guilan Li, Yu-Tzu Tai, Klaus Podar, Dharminder Chauhan, Kenneth C. Anderson

Blood (2004) 104 (11): 3456.

https://doi.org/10.1182/blood.V104.11.3456.3456

Published: 2004

Journal Articles

SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma.

Makoto Hamasaki, Teru Hideshima, Kenji Ishitsuka, Hiroshi Yasui, Norihiko Shiraishi, Shaji Kumar, Noopur Raje, Aldo M. Roccaro, Yu-Tzu Tai, Reshma Shiringarpure, Lorenzo Leoni, Sarath Kanekal, Gary Elliott, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2004) 104 (11): 3466.

https://doi.org/10.1182/blood.V104.11.3466.3466

Published: 2004

Journal Articles

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

Teru Hideshima, MD, PhD, Klaus Podar, MD, PhD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Constantine Mitsiades, MD, PhD, Yu-Tzu Tai, PhD, Makoto Hamasaki, MD, PhD, Noopur Raje, MD, Hiromasa Hideshima, George Schreiner, MD, PhD, Aaron Nguyen, PhD, Tony Navas, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Linda S. Higgins, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 3348.

https://doi.org/10.1182/blood.V104.11.3348.3348

Published: 2004

Journal Articles

A Novel Inosine Monophosphate Dehydrogenase Inhibitor VX-944 Overcomes Conventional Drug-Resistance in Multiple Mueloma Cells in the Bone Marrow Microenvironment.

Kenji Ishitsuka, M.D., Ph.D, Teru Hideshima, M.D., Ph.D, Makoto Hamasaki, M.D., Ph.D, Raje Noopur, M.D., Ph.D, Kumar Shaji, M.D., Ph.D, Hiroshi Yasui, M.D., Ph.D, Aldo M. Roccaro, M.D., Dharminder Chauhan, Ph.D, Klaus Podar, M.D., Ph.D, Yu-Zu Tai, Ph.D, Jugnu Jain, Ph.D, Kenneth C. Anderson, M.D., Ph.D

Blood (2004) 104 (11): 2468.

https://doi.org/10.1182/blood.V104.11.2468.2468

Published: 2004

Journal Articles

Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.

Teru Hideshima, MD, PhD, Pierfrancesco Tassone, MD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Constantine Mitsiades, MD, PhD, Noopur Raje, MD, Shaji Kumar, MD, Makoto Hamasaki, MD, PhD, Hiromasa Hideshima, Nikhil C. Munshi, MD, Paul G. Richardson, MD, David Schenkein, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2351.

https://doi.org/10.1182/blood.V104.11.2351.2351

Published: 2004

Journal Articles

TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.

Toshiaki Hayashi, MD, PhD, Teru Hideshima, MD, PhD, Klaus Podar, MD, PhD, Paul Richardson, MD, Olivier Munoz, MD, Makoto Hamasaki, MD, PhD, Kenji Ishitsuka, MD, PhD, Hiroshi Yasui, MD, PhD, Alison Murphy, PhD, Glenn McEnroe, PhD, Sarvajit Chakravarty, PhD, Sundeep Dugar, PhD, Linda S. Higgins, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2355.

https://doi.org/10.1182/blood.V104.11.2355.2355

Published: 2004

Journal Articles

Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.

Makoto Hamasaki, Teru Hideshima, Pierfrancesco Tassone, Paola Neli, Kenji Ishitsuka, Masaharu Akiyama, Toshiaki Hayashi, Hiroshi Yasui, Norihiko Shiraishi, Dharminder Chauhan, Constantine Mitsiades, Klaus Podar, Deepak Gupta, Donald H. Picker, Gary S. Jacob, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2004) 104 (11): 2401.

https://doi.org/10.1182/blood.V104.11.2401.2401

Published: 2004

Journal Articles

Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues.

Shaji Kumar, MD, Noopur Raje, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Aldo Roccaro, MD, Norihiko Shiraishi, MD, Makoto Hamasaki, MD, Hiroshi Yasui, MD, Nikhil C. Munshi, MD, William D. Figg, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2406.

https://doi.org/10.1182/blood.V104.11.2406.2406

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma

Biological Pathways and In Vivo Anti-Tumor Activity Induced by Atiprimod in Multiple Myeloma (MM).

In Vivo Anti-Tumor Activity of Atiprimod on SCID Models of Multiple Myeloma.

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma

Azaspirane ( N-N -diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo

Induction of Apoptosis by Didox Via Down-Regulation of Bcl-2 Family Proteins in Multiple Myeloma (MM).

Bortezomib Targets Multiple Myeloma Endothelial Cells.

Honokiol Overcomes Conventional Drug Resistance in Human Multiple Myeloma.

Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.

The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells.

In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM).

Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma.

SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma.

P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.

A Novel Inosine Monophosphate Dehydrogenase Inhibitor VX-944 Overcomes Conventional Drug-Resistance in Multiple Mueloma Cells in the Bone Marrow Microenvironment.

Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.

TGF-β Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.

Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.

Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only